3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Pancreatic Neoplasms
24
Colorectal Neoplasms
16
Small Cell Lung Carcinoma
6
Stomach Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Biliary Tract Neoplasms
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Recurrence
3
Rectal Neoplasms
3
Osteosarcoma
3
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Cholangiocarcinoma
2
Wilms Tumor
1
Weight Loss
1
Triple Negative Breast Neoplasms
1
Somatostatinoma
1
Solid Tumor Cancer
1
Solid Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Small Bowel Adenocarcinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Interventions
Everolimus
7
Nivolumab
6
Cisplatin
6
Temozolomide
5
Bevacizumab
5
lutetium Lu 177 dotatate
4
Fluorouracil
4
Carboplatin
4
pembrolizumab
3
avelumab
3
atezolizumab
3
Irinotecan
3
Ipilimumab
3
Etoposide
3
Capecitabine
3
surufatinib
2
sintilimab
2
gallium Ga 68 dotatate
2
dostarlimab
2
Radiosurgery
2
Positron Emission Tomography Computed Tomography
2
Paclitaxel
2
PE regimen
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Magnetic Resonance Imaging
2
Immunoglobulin G
2
IFL protocol
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Neuroendocrine
×
irinotecan sucrosofate
×
Clear all
NCT03837977
2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2
Completed
58 enrolled